Phase 3 Migraine Trial, Recruiting NCT06641466 Sponsor: Pfizer Condition: Migraine
Back to Migraine

Phase 3 Migraine Trial, Recruiting

NCT06641466
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have regular menstrual cycles that are between 24 and 34 days long
  • You have been diagnosed with migraine (with or without aura) for at least 1 year, following standard medical guidelines
  • You have had migraines linked to your menstrual cycle for at least 3 months
  • In at least 2 out of your last 3 menstrual cycles, you had at least 1 migraine around the time of your period
  • If you are already taking a regular medication to prevent migraines, the dose has been stable for at least 3 months and is not expected to change during the study

Who may not be able to join:

  • You have more than 6 migraine days per month that happen outside of your period window, in the 3 months before screening
  • You have been diagnosed with chronic migraine, or you have had more than 14 headache days per month on average in the last 3 months
  • You have a history of certain specific types of migraine, including retinal migraine, basilar migraine, or hemiplegic migraine
  • You currently have a diagnosis of schizophrenia, bipolar disorder, or borderline personality disorder
  • You have other significant pain conditions (such as fibromyalgia), serious neurological conditions (other than migraine), or certain other medical conditions including severe period pain or hormonal/gynecological disorders (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Pfizer CT.gov Call Center, Pfizer

Phone: 1-800-718-1021

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Registry
ClinicalTrials.gov
Start date
11 March 2025
Est. completion
29 November 2026

Where this trial is recruiting

🇦🇷 Argentina 🇨🇦 Canada 🇨🇳 China 🇩🇰 Denmark 🇩🇪 Germany 🇮🇳 India 🇮🇹 Italy 🇯🇵 Japan 🇲🇽 Mexico 🇳🇱 Netherlands 🇵🇱 Poland 🇰🇷 South Korea 🇪🇸 Spain 🇬🇧 United Kingdom 🇺🇸 United States

Primary endpoints

Mean change from the Observation Period in number of migraine days per 5-day perimenstrual period across each cycle of the Double-Blind Treatment Phase

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov